Biography
Noemi Lois
Queen's University, UK
Noemi Lois is a Professor of Ophthalmology at Queens University and an Honorary Consultant Ophthalmologist and Vitreoretinal Surgeon at the Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK. After having obtained her medical degree, Noemi did her Residency in Ophthalmology and PhD degree in Spain and then completed fellowships in 1) Ocular Oncology at Wills Eye Hospital, Philadelphia, with Drs Jerry and Carol Shields, 2) Medical Retina at Moorfields Eye Hospital, London, with Prof Alan Bird, and 3) Vitreoretinal Surgery at The Royal Liverpool University Hospital, Liverpool, with Prof David Wong. Noemi then moved to Aberdeen, Scotland, where she worked as full time Consultant Ophthalmic Surgeon for 13 years and then joined Queens University, Belfast, in 2013 where she has been leading a programme of preclinical and clinical research focused on complications of diabetic retinopathy and vitreoretinal surgery. This programme of research extends from pathogenic mechanisms of disease and risk stratification to new therapies, including determining the most cost-effective therapeutic alternatives for this disease.
Noemi has published over 170 articles in peer review journals (Scopus h-index 48), 13 book chapters and is editor of 3 textbooks, one is on its second edition. Noemi is an ad-hoc referee for numerous peer-review journals and funding bodies and has given numerous lectures as guest speaker at national and international meetings in the UK and aboard (China, Denmark, Germany, India, Indonesia, Ireland, Italy, Japan, Malaysia, Mexico, Pakistan, Singapore, South Africa, Spain, Switzerland and the USA). Noemi is editorial board member for several journals including the Cochrane Eyes and Vision Group. Noemi participated, as a member of the Evidence Review Group, in 10 Single Technology Appraisals for the UK National Institute of Health and Care Excellence (NICE) on new therapies for retinal diseases. She was awarded the King James IV Professorship by the Royal College of Surgeons of Edinburgh in 2024 and delivered the corresponding lecture at the Annual Meeting of the Royal College of Ophthalmologists. She delivered the Meyer-Schwickerath Lecture at the 36th International Congress of German Ophthalmic Surgeons (DOC) in Nuremberg in 2024, and the Mila Oh’s Memorial Lecture at the 2025 annual meeting of the Canadian Retina Society.
Noemi has been Chief Investigator of several publicly funded multi-centre trials, including FILMS, on surgical techniques for macular hole (funded by the Chief Scientist Office, Scotland - Lois N et al. Invest Ophthalmol Vis Sci. 2011;52(3):1586-1592), DIAMONDS, on laser surgery for diabetic macular oedema (funded by the Health Technology Assessment of the National Institute for Health and Care Research, HTA-NIHR - Lois N et al. Trials. 2019;20(1):122; Lois N et al. Ophthalmology. 2023 Jan;130(1):14-27; Lois N et al. Health Technol Assess. 2022 Dec;26(50):1-86) and EMERALD, on multimodal imaging and new pathways of care for people with complications of diabetic retinopathy (funded by the NIHR HTA – Lois N et al. BMJ Open. 2019;9(6):e027795; Lois N et al. Health Technol Assess. 2021 May;25(32):1-104; Lois N et al. Ophthalmology. 2021 Apr;128(4):561-573; Maredza M, Mistry H, Lois N, et al. Br J Ophthalmol. 2022 Nov;106(11):1549-1554; Prior L, Lois N; EMERALD Study Group. Eye 2023;37:1155-1159). Noemi is co-lead of RECOGNISED, a multicentric consortium investigating diabetes, cognitive impairment and dementia, funded by the EU Horizon 2020, and has just recently received HTA-NIHR-support to conduct two large UK-wide randomized clinical trials which will commence this year: DAME, which will compare clinical effectiveness, cost-effectiveness, patient experience and acceptability of anti-VEGF therapies versus combined anti-VEGF therapy and subthreshold micropulse laser (SML) for people with severe diabetic macular oedema, with SML applied once central retinal thickness goes below 400 microns following anti-VEGFs; and COMBAT: To determine clinical and cost-effectiveness, safety and patient experience and acceptability of phacovitrectomy, compared with vitrectomy and subsequent cataract surgery (if/when needed), for non-highly myopic phakic rhegmatogenous retinal detachment, and to set basis for its implementation.